Edgewise Therapeutics
Laura Emery is a seasoned professional with 20 years of experience in clinical development, primarily focusing on cardiology, pulmonology, and gastroenterology. Currently serving as the Director of Clinical Operations at Gossamer Bio since November 2022, Laura also operates as an independent consultant through Emery Research Consulting. Previous roles include Head of Clinical Operations at Lung Therapeutics, Inc., and Sr. Director of Clinical Operations at ARCA biopharma Inc. Notable experience encompasses managing clinical trials for various pharmaceutical companies, leading significant projects in pulmonary arterial hypertension, and developing innovative therapies for conditions like iron deficiency anemia. Laura holds an MSPH in Public Health and a BS in Biology from reputable institutions.
This person is not in any teams
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.